OneMedNet Corp (ONMD) shareholders
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Off the Chain LP Joint filing with Off the Chain Capital, LLC (9.50%) | 3,215,650 | 9.50% | 13G (passive) | Sep 25, 2024 |
| Td Securities (USA) LLC | 3,025,338 | 6.20% | 13G (passive) amendment | Sep 30, 2025 |
| Cowen and Company, LLC | 2,970,836 | 9.50% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ONMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Savant Capital, LLC | 721,924 | – | $5.14M | New | 0.02% |
| Vanguard Capital Management LLC | 115,221 | – | $819.22K | +3,664 | 0.00% |
| Geode Capital Management, LLC | 33,433 | – | $237.71K | −420 | 0.00% |
| Vanguard Fiduciary Trust Co | 13,771 | – | $97.91K | +110 | 0.00% |
| BlackRock, Inc. | 12,098 | – | $86.02K | +5,088 | 0.00% |
| State Street Corp | 11,670 | – | $82.97K | – | 0.00% |
| Discovery Capital Management, LLC / Ct | 11,225 | – | $79.81K | – | 0.00% |
| PNC Financial Services Group, Inc. | 10,333 | – | $73.47K | +8,607 | 0.00% |
| OpenArc Corporate Advisory, LLC | 9,741 | – | $69.26K | +8,607 | 0.00% |
| Northern Trust Corp | 4,684 | – | $33.30K | −810 | 0.00% |
| Captrust Financial Advisors | 3,260 | – | $23.18K | New | 0.00% |
| Ashton Thomas Private Wealth, LLC | 2,660 | – | $18.91K | – | 0.00% |
| Toronto Dominion Bank | 2,360 | – | $16.78K | New | 0.00% |
| Neuberger Berman Group LLC | 1,950 | – | $13.87K | – | 0.00% |
| UBS Group AG | 1,614 | – | $11.47K | −10 | 0.00% |
| Hrt Financial LP | 1,563 | – | $11.00K | −2,845 | 0.00% |
| Procyon Advisors, LLC | 1,381 | – | $9.82K | – | 0.00% |
| Raymond James Financial Inc | 1,210 | – | $8.60K | – | 0.00% |
| Morgan Stanley | 1,182 | – | $8.41K | New | 0.00% |
| Commonwealth Equity Services, LLC | 1,100 | – | $7.82K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 22 | 1M | 6 / 5 | 4 / 4 | 1M | 0M |
| Q1 2026 | 21 | 1M | 6 / 7 | 1 / 7 | 1M | 0M |
| Q4 2025 | 23 | 1M | 10 / 7 | 3 / 4 | 0M | 1M |
| Q3 2025 | 17 | 1M | 6 / 5 | 1 / 4 | 1M | 0M |
| Q2 2025 | 15 | 1M | 3 / 2 | 3 / 5 | 0M | 0M |
| Q1 2025 | 17 | 0M | 2 / 4 | 6 / 2 | 0M | 0M |
| Q4 2024 | 17 | 0M | 2 / 3 | 7 / 5 | 0M | 0M |
| Q3 2024 | 20 | 1M | 9 / 2 | 6 / 3 | 0M | 0M |
| Q2 2024 | 14 | 0M | 11 / 3 | 0 / 4 | 0M | 0M |
| Q1 2024 | 7 | 0M | 4 / 2 | 1 / 3 | 0M | 0M |
| Q4 2023 | 6 | 0M | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
10 funds held ONMD in Q2 2026, 82% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ONMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 845,040 | – | $600.82K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 307,170 | – | $218.40K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 158,498 | – | $122.14K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 47,503 | – | $33.77K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 43,207 | – | $33.30K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 41,177 | – | $31.73K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 29,823 | – | $22.98K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 3,381 | – | $2.40K | 0.00% | Jun 30, 2026 |
| Avantis Total Equity Markets ETF | 909 | – | $700 | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -6,069 | – | -$4.32K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Jeffrey Yu | Chief Medical Officer, Director, 10% owner | 1,028,037 | Oct 13, 2026 |
| Aaron Green | Chief Executive Officer, Director | 247,971 | Oct 9, 2026 |
| Robert Lawrence Golden | Chief Financial Officer, Director | 91,291 | Oct 9, 2026 |
| Thomas Kosasa | Director, 10% owner | 1,983,573 | Oct 13, 2026 |
| Kenneth Alleyne | Director | 38,219 | Nov 26, 2025 |
| Andrew B. Zeinfeld | Director | 381,525 | Nov 26, 2025 |
| Sherry Coonse McCraw | Director | 56,342 | Nov 26, 2025 |
| Eric Casaburi | Director | 110,475 | Nov 26, 2025 |
| Jair Clarke | Director | 138,485 | Nov 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Oct 9, 2026 | Buy | +45,126 | $5.54 | $250.00K | 896,840 |
| Thomas Kosasa Director, 10% owner | Oct 7, 2026 | Buy | +129,758 | $5.78 | $750.00K | 1,983,573 |
| Aaron Green Chief Executive Officer, Director | Sep 24, 2026 | Sale | −1,667 | $6.48 | $10.80K | 247,971 |
| Aaron Green Chief Executive Officer, Director | Sep 22, 2026 | Sale | −5,000 | $7.39 | $36.96K | 249,638 |
| Robert Lawrence Golden Chief Financial Officer, Director | Sep 21, 2026 | Sale | −3,000 | $6.63 | $19.89K | 91,291 |
| Robert Lawrence Golden Chief Financial Officer, Director | Sep 15, 2026 | Sale | −3,000 | $6.30 | $18.90K | 94,291 |
| Robert Lawrence Golden Chief Financial Officer, Director | Sep 14, 2026 | Sale | −2,500 | $6.60 | $16.50K | 97,291 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Sep 10, 2026 | Buy | +142,857 | $0.63 | $90.00K | 8,923,267 |
| Thomas Kosasa Director, 10% owner | Jul 30, 2026 | Buy | +1,449,275 | $0.69 | $1,000.00K | 18,538,150 |
| Robert Lawrence Golden Chief Financial Officer, Director | Jul 6, 2026 | Award | +35,000 | – | – | 99,791 |
| Aaron Green Chief Executive Officer, Director | Jul 6, 2026 | Award | +65,000 | – | – | 254,638 |
| Aaron Green Chief Executive Officer, Director | Jun 23, 2026 | Buy | +36,650 | $0.57 | $20.89K | 1,896,375 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Jun 23, 2026 | Buy | +158,730 | $0.63 | $100.00K | 8,780,410 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Jun 16, 2026 | Buy | +172,414 | $0.58 | $100.00K | 8,621,680 |
| Aaron Green Chief Executive Officer, Director | Jun 15, 2026 | Buy | +18,702 | $0.54 | $10.10K | 1,859,725 |
| Aaron Green Chief Executive Officer, Director | Jun 12, 2026 | Buy | +36,920 | $0.56 | $20.68K | 1,841,023 |
| Thomas Kosasa Director, 10% owner | Jun 12, 2026 | Buy | +158,730 | $0.63 | $100.00K | 17,088,874 |
| Thomas Kosasa Director, 10% owner | May 18, 2026 | Buy | +268,817 | $0.93 | $250.00K | 16,930,144 |
| Thomas Kosasa Director, 10% owner | Apr 23, 2026 | Buy | +280,898 | $0.89 | $250.00K | 16,661,327 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Apr 1, 2026 | Award | +219,429 | $0.83 | $182.13K | 8,449,266 |
| Jeffrey Yu Chief Medical Officer, Director, 10% owner | Apr 1, 2026 | Buy | +903,614 | $0.83 | $750.00K | 8,229,837 |
| Thomas Kosasa Director, 10% owner | Feb 6, 2026 | Buy | +595,238 | $0.84 | $500.00K | 16,380,429 |
| Robert Lawrence Golden Chief Financial Officer, Director | Jan 1, 2026 | Award | +10,000 | – | – | 64,791 |
| Eric Casaburi Director | Nov 26, 2025 | Award | +45,000 | – | – | 110,475 |
| Kenneth Alleyne Director | Nov 26, 2025 | Award | +38,219 | – | – | 38,219 |
| Jair Clarke Director | Nov 26, 2025 | Award | +45,000 | – | – | 138,485 |
| Jeffrey Yu Chief Medical Officer, Director | Nov 26, 2025 | Award | +45,000 | – | – | 7,326,223 |
| Sherry Coonse McCraw Director | Nov 26, 2025 | Award | +45,000 | – | – | 56,342 |
| Thomas Kosasa Director | Nov 26, 2025 | Award | +45,000 | – | – | 15,785,191 |
| Andrew B. Zeinfeld Director | Nov 26, 2025 | Award | +45,000 | – | – | 381,525 |
| Aaron Green Chief Executive Officer, Director | Nov 26, 2025 | Award | +45,000 | – | – | 1,930,425 |
| Robert Lawrence Golden Chief Financial Officer, Director | Nov 26, 2025 | Award | +45,000 | – | – | 547,905 |
| Jeffrey Yu Chief Medical Officer, Director | Nov 24, 2025 | Award | +200,000 | – | – | 7,281,223 |
| Aaron Green Chief Executive Officer, Director | Nov 24, 2025 | Award | +1,000,000 | – | – | 1,885,425 |
| Robert Lawrence Golden Chief Financial Officer, Director | Nov 24, 2025 | Award | +33,333 | – | – | 502,905 |
| Robert Lawrence Golden Chief Financial Officer, Director | Nov 24, 2025 | Award | +300,000 | – | – | 469,572 |
| Aaron Green Chief Executive Officer, Director | Nov 18, 2025 | Sale | −61,555 | $1.20 | $73.87K | 1,804,103 |
| Aaron Green Chief Executive Officer, Director | Oct 22, 2025 | Sale | −64,767 | $2.23 | $144.43K | 1,865,658 |
| Eric Casaburi Director | Oct 15, 2025 | Buy | +10,000 | $3.05 | $30.50K | 65,475 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 25, 2025 | Buy | +1,250 | $1.03 | $1.29K | 7,081,223 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 24, 2025 | Buy | +17,200 | $1.02 | $17.54K | 7,079,973 |
| Thomas Kosasa Director | Sep 24, 2025 | Buy | +6,000 | $0.93 | $5.58K | 15,740,191 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 23, 2025 | Buy | +5,700 | $0.93 | $5.30K | 7,062,773 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 22, 2025 | Buy | +400 | $0.95 | $380 | 7,057,073 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 19, 2025 | Buy | +1,250 | $0.89 | $1.11K | 7,056,673 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 18, 2025 | Buy | +700 | $0.91 | $637 | 7,055,423 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 5, 2025 | Buy | +2,100 | $0.86 | $1.81K | 7,054,723 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 4, 2025 | Buy | +11,810 | $0.87 | $10.27K | 7,052,623 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 3, 2025 | Buy | +11,670 | $0.81 | $9.45K | 7,040,813 |
| Jeffrey Yu Chief Medical Officer, Director | Sep 2, 2025 | Buy | +24,319 | $0.85 | $20.67K | 7,029,143 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 29, 2025 | Buy | +10,890 | $0.82 | $8.93K | 7,004,824 |
| Thomas Kosasa Director | Aug 29, 2025 | Buy | +581,395 | $0.86 | $500.00K | 15,734,191 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 28, 2025 | Buy | +17,000 | $0.80 | $13.60K | 6,993,934 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 27, 2025 | Buy | +21,374 | $0.69 | $14.75K | 6,976,934 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 26, 2025 | Buy | +173,350 | $0.69 | $119.61K | 6,955,560 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 25, 2025 | Buy | +13,300 | $0.75 | $9.98K | 6,782,210 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 21, 2025 | Buy | +15,000 | $0.77 | $11.55K | 6,768,910 |
| Jeffrey Yu Chief Medical Officer, Director | Aug 19, 2025 | Buy | +16,500 | $0.77 | $12.71K | 6,753,910 |
| Jeffrey Yu Chief Medical Officer, Director | Jun 20, 2025 | Buy | +1,666,666 | $0.42 | $700.00K | 6,737,410 |
| Thomas Kosasa Director | Jun 20, 2025 | Buy | +1,190,476 | $0.42 | $500.00K | 15,152,796 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of OneMedNet's stock actually held short. Settlement fails (shares not delivered on time) peaked at 442,680 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?